Effects of romosozumab on bone mineral density and fractures in postmenopausal women: a meta-analysis
Open Access
- 18 July 2024
- journal article
- review article
- Published by Sri Lanka Journals Online in Journal of the Ceylon College of Physicians
- Vol. 55 (1) , 29-35
Abstract
Purpose: Romosozumab, a mono-clonal antibody has been approved for the treatment of postmenopausal women with osteoporosis and high fracture risk. This meta-analysis evaluated the effect of romosozumab on Bone Mineral Density (BMD) and fracture occurrence in postmenopausal women with osteoporosis.Methods: A systematic search was done adhered to the PRISMA guidelines in PubMed, Ovid and Clinicaltrials.gov and eligible studies were selected. The details related to study participants, changes in BMD at the lumber spine (LS), total hip (TH) and femoral neck (FN) and the occurrence of fractures during the period were extracted. The mean differences of BMDs between the two groups and odds ratios (OR) of fractures were considered as the outcome of the studies.Results: Of the 11 potentially eligible articles, only four studies fulfilled the selection criteria and they were included in the final analysis. Romosozumab therapy for 12 months increased mean BMD at the LS by 12.7% (95% CI, 9.7, 15.6), TH by 4.8% (95% CI, 3.3,6.3) and FN by 4.1% (95% CI, 3.1, 5.2). Treatment with romosozumab decreased the odds of new vertebral fractures and vertebral fractures by 58% (OR=0.42, CI, 0.23,0.91) and 25% (OR=0.75, CI, 0.53,1.06) respectively at the end of 12 months.Conclusion: Romosozumab significantly increases BMD at LS, TH and FN and reduces the risk of new vertebral and non-vertebral fractures in postmenopausal women with osteoporosis.Keywords
This publication has 21 references indexed in Scilit:
- Evaluation of the efficacy and safety of romosozumab (evenity) for the treatment of osteoporotic vertebral compression fracture in postmenopausal women: A systematic review and meta‐analysis of randomized controlled trials (CDM‐J)Pharmacoepidemiology and Drug Safety, 2023
- Medical expenditures for fragility hip fracture in Japan: a study using the nationwide health insurance claims databaseArchives of Osteoporosis, 2022
- Romosozumab and antiresorptive treatment: the importance of treatment sequenceOsteoporosis International, 2022
- Cost of hospitalisation for hip fracture—findings from the Irish hip fracture databaseOsteoporosis International, 2022
- The clinical and economic burden after an osteoporosis fracture in France: a nationwide population-based studyArchives of Osteoporosis, 2021
- Romosozumab: a Review of Efficacy, Safety, and Cardiovascular RiskCurrent Osteoporosis Reports, 2021
- Romosozumab: A Review in Postmenopausal OsteoporosisDrugs & Aging, 2020
- Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone MassJournal of Bone and Mineral Research, 2016
- Secular trends in the incidence of hip and other osteoporotic fracturesOsteoporosis International, 2011
- Evidence‐based Obstetric Anesthesia2005